ALKYL [(S)-1-((S)-2-{5-[4-(4-{2-[(S)-1-((S)-2-METHOXYCARBONYLAMINO-3-METHYL-BUTYRYL)-PYRROLIDINE-2-YL]-3H-IMIDAZOLE-4-YL}-BUTA-1,3-DIENYL)-PHENYL]-1H-IMIDAZOLE-2-YL}-PYRROLIDINE-1-CARBONYL)-2-METHYL-PROPYL]-CARBAMATE NAPHTHALENE-1,5-DISULFONATE, PHARMACEUTICAL COMPOSITION, MEDICINAL AGENT AND METHOD FOR TREATMENT OF VIRAL DISEASES

摘要

The present invention relates to NS5A inhibitors, to a novel pharmaceutical composition, to an antiviral medicinal agent, and to a method for the prevention and treatment of viral diseases, particularly those caused by the hepatitis C (HCV) and hepatitis GBV-C viruses. Proposed are alkyl [(S)-1-((S)-2-{5-[4-(4-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidine-2-yl]-3H-imidazole-4-yl}-buta-1,3-dienyl)-phenyl]-1H-imidazole-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamate naphthalene-1,5-disulfonate of general formula 1, in crystalline or polycrystalline form, where: R is C1-C3 alkyl.